KYMR · Kymera Therapeutics, Inc.

Current Thesis

Kymera Therapeutics’ oral eczema treatment thesis requires positive BROADEN2 results and renewed price strength by year-end 2026 before a weekly close below $100 breaks the case. The success condition remains a reported primary-endpoint success followed by a weekly close above $127.31 by 2026-12-31. The clinical deadline comes from management’s 2026-09-01 guidance; $127.31 is the market’s 52-week high in the adjusted price series dated 2026-09-18. Clinical announcement

The inference remains that the narrative is maturing — enrollment acceleration was announced on 2026-06-25, while September’s clinical presentations feature previously reported results. Fresh controlled efficacy accompanied by a weekly close above the September 18 reference high would overturn that assessment. The dependence on a discrete trial result supports the Binary Catalyst classification. Enrollment announcement September clinical announcement

Since the September 11 note, the September 14 and 15 investor appearances have moved into the company’s event archive. As checked on 2026-09-20, its press-release index still ends with the September 2 conference announcement: that index supplies no subsequent release resolving efficacy or narrowing the readout date. This does not establish what management said in the archived webcasts. Company events Release index

Bullish and bearish views on Kymera Therapeutics, Inc.

The model's bull view on Kymera Therapeutics, Inc. (KYMR), in brief: Enrollment brought the deadline forward. The bear view: Controlled efficacy remains the hurdle. The 2026-06-25 trial description specifies approximately 200 patients, three doses versus placebo and treatment over 16 weeks. The primary endpoint measures percentage change in the Eczema Area and Severity Index at Week 16; enrollment… Both cases follow in full.

Bull Case

• Enrollment brought the deadline forward. Kymera’s 2026-06-25 announcement reported BROADEN2 enrollment completion nearly six months ahead of schedule. Execution supports the timetable argument; guidance moving beyond 2026-12-31 would invalidate it. Enrollment announcement
• Cash supports the development window. The 2026-08-05 financial update reported $1.5 billion in cash, cash equivalents and investments at 2026-06-30, with management projecting runway into 2029. Funding through the readout is an inference from that guidance; a revised runway ending before the readout would contradict it. Quarterly results

Bear Case

• Controlled efficacy remains the hurdle. The 2026-06-25 trial description specifies approximately 200 patients, three doses versus placebo and treatment over 16 weeks. The primary endpoint measures percentage change in the Eczema Area and Severity Index at Week 16; enrollment completion supplies no result for that endpoint. Trial announcement
• Conference exposure reuses earlier evidence. Kymera’s 2026-09-01 announcement explicitly describes the September congress posters as previously reported Phase 1b data. Those presentations cannot establish BROADEN2 success; a reported primary-endpoint failure would break the clinical thesis. Clinical announcement

Setup & Price Structure

The measured 2026-09-18 adjusted close was $117.75, with a three-month price increase of 18.4% and a reported distance of 7.5% below the $127.31 52-week high. The 14-day relative strength index was 48.8 in the same dated snapshot. These observations establish prior appreciation and a price below the reference high; they do not establish a renewed breakout.

The $100 threshold remains the research invalidation published on 2026-09-11. The September 18 snapshot contains no moving-average values or historical volume profile, so it cannot independently reconfirm the earlier note’s description of that level as a breakout base.

Observable attention is clustered: the company’s 2026-09-02 announcement scheduled investor appearances on September 9, 10, 14, 15 and 24. Conference density measures exposure, not ownership crowding. Current retail-sentiment counts, updated short interest and dated insider-sale evidence are missing from the evidence reviewed; no positioning conclusion follows. Conference announcement

Catalyst Calendar (next 30 days)

• 2026-09-24 — Stifel immunology forum. The company lists the Stifel Virtual Immunology and Inflammation Forum for this date. It is the next confirmed management appearance; the listing does not promise new trial results. Company events
• 2026-09-30 through 2026-10-03 — Dermatology congress. The European Academy of Dermatology & Venereology congress includes KT-621 ePoster P1540 on itching and sleep outcomes. The September 1 announcement identifies earlier Phase 1b results and provides no specific poster-session date. Clinical announcement
• 2026-12-31 — BROADEN2 guidance deadline. This later date represents the end of management’s year-end reporting window, not a scheduled release day. The June 25 announcement makes the controlled eczema trial the event on which the thesis turns. Enrollment announcement

What Would Change Our Mind

Loss of the retained September 11 research threshold would end the price case: a weekly close below $100 is the observable condition. Independently, a reported BROADEN2 primary-endpoint failure or 2026-12-31 passing without topline results would defeat the clinical or timing premise established by the June 25 announcement. Trial and timetable

Conviction remains low because the published outcome requires both controlled clinical success and a subsequent weekly close above the September 18 high of $127.31 within the stated deadline. The available evidence establishes enrollment completion and financial runway; it does not establish that combined outcome.

Correlation Notes

This remains a single-company clinical setup. Kymera’s 2026-06-25 announcement ties the central milestone to BROADEN2, and the September 18 price snapshot supplies no peer-return series or correlation estimate. The evidence is insufficient to claim that biotechnology-sector strength or immunology acquisition activity predicts this trial’s result. Company-specific milestone